

HEAL Pain Strategic Planning Subcommittee Co-Chairs:

Yenisel Cruz-Almeida, MSPH, PhD & Vivianne Tawfik, MD, PhD

BIOMARKERS & PREDICTORS SUBCOMMITTEE

PUBLIC VIRTUAL SESSION

WEDNESDAY, NOVEMBER 6^{TH} , 2024



Biomarkers & Predictors Subcommittee

- Sandip Biswal, MD University of Wisconsin
- Susan Dorsey, PhD, RN, FAAN University of Maryland
- Aaron Fields, PhD UC San Francisco
- Peter Grace, PhD MD Anderson Cancer Center
- Sean Mackey, MD, PhD Stanford University
- Christin Veasley (PWLE) Co-Chair NIH ENGAGE & HEAL initiative committees
- Christine Von Raesfeld (PWLE) NIH All of Us Program (& many others)
- Tor Wager, PhD Dartmouth College



Definition of Biomarkers


A defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or biological responses to an exposure or intervention, including therapeutic interventions.

- molecular,
- histological,
- radiographic, or
- physiological characteristics.

FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US); [last updated 2021 Nov 29].



Types of Biomarkers



Adapted from Meditrial



The Importance of Biomarkers

Understand pain mechanisms

- Improve clinical trial design:
 - Identify and select appropriate patients
 - Monitor treatment efficacy
 - Develop surrogate endpoints




The Importance of Biomarkers

- Personalized Pain Management:
 - Identifying different pain subtypes
 - Predicting treatment response
- Development of safer and more effective pain therapies-not addictive:
 - Identifying new targets
 - Monitoring safety and efficacy of novel therapies.



HEAL Workshop 2024





HEAL Workshop 2024





15-Minute Break



Meeting resumes at 3:00 PM ET